Patients with a history of intracranial hemorrhage have had few safe treatment options for nonvalvular atrial fibrillation. A new study of the Watchman device suggests that may be changing.
Findings from three Cleveland Clinic real-world studies suggest a wider range of patients stand to benefit from the left atrial appendage closure device.
The newly approved WATCHMAN™ device can prevent stroke in high-risk patients with nonvalvular atrial fibrillation. But when exactly is left atrial appendage closure preferable to warfarin therapy?